GETINGE BCG MATRIX TEMPLATE RESEARCH
Unlock Strategic Clarity
Getinge's BCG Matrix preview highlights how its core product lines map to market growth and relative share-hinting at Stars in advanced OR solutions, Cash Cows in sterilization, and Question Marks in emerging digital therapies; this snapshot helps prioritize where management should invest or divest. Purchase the full BCG Matrix for quadrant-by-quadrant data, actionable recommendations, and downloadable Word and Excel files to guide capital allocation and product strategy with confidence.
Stars
Advanced Mechanical Ventilators and ICU Solutions
Getinge holds an 11.5% global ventilator market share at end-2025, benefiting from industry consolidation and an 8.6% sector CAGR; ventilators remain a top revenue driver after generating SEK 9.2bn in 2025 sales for advanced respiratory care.
Production capacity increased to 26,000 units/year to meet aging populations and rising chronic respiratory disease; ongoing R&D spend of SEK 420m in 2025 targets AI-enabled monitoring and automated ventilation modes.
The 2025 Servo-c launch in India and other emerging markets boosted unit shipments by 18% year-over-year, reinforcing this high-growth, high-share Star position in Getinge's portfolio.
Sterile Transfer Systems and Life Science Solutions
Getinge's Life Science hit record 2025 sales, led by DPTE® Sterile Transfer with 45,000 units in operation and DPTE-BetaBag® single-use variants growing at a 12.5% CAGR and over 2 million lifetime units.
As biologics and personalized medicine expand, Getinge holds a 25-30% combined market share in sterile ports, marking dominant positioning.
High growth requires heavy capital: 2025 capex rose to support manufacturing automation and global expansion, sustaining the competitive moat.
Extracorporeal Life Support (ECLS) Consumables
Extracorporeal Life Support (ECLS) consumables-oxygenators and tubing sets-are a Star for Getinge, driven by strong organic growth through 2025 and the Cardiohelp ECMO system anchoring critical-care adoption.
Market forecasts peg the ECMO consumables market at $790 million by 2034; Getinge's consumables and disposables contributed to a recurring-revenue share that rose to 66% of Group sales by late 2025.
Getinge maintains a leading ECMO position; Rotaflow consumables secured EU MDR approval in late 2025, but ongoing investment is essential to meet regulatory demands and scale production against rising global demand.
Transplant Care and Paragonix Integration
Getinge's 2024 Paragonix acquisition became a Star, driving >20% sales growth in FY2025 and lifting segment EBITA to 18%-ahead of company forecasts-on strong KidneyVault uptake after FDA 510(k) clearance.
KidneyVault expands Getinge's transplant portfolio into the largest organ-by-volume market; portable perfusion gives a first-to-market edge in a niche projected to grow ~12% CAGR through 2028.
- 2025 sales growth: >20%
- 2025 segment EBITA margin: ~18%
- KidneyVault: FDA 510(k) cleared (2025)
- Target markets: EU, APAC expansion underway
- Market CAGR (portable perfusion niche): ~12% to 2028
Digital Health Solutions and Hospital Efficiency Software
Getinge's Digital Health Solutions became a Star in 2025, delivering double-digit organic growth as hospitals adopt data-driven workflow optimization and surgical/sterile-reprocessing software that cuts human error.
R&D was SEK 1,452 million in 2025, with a large share into digital platforms now embedded in surgical workflows, driving market share gains and SaaS transition.
These solutions are set to become high-margin Cash Cows as recurring SaaS revenue scales; digital services now represent an increasing portion of aftermarket revenue.
- 2025 R&D: SEK 1,452 million
- Segment: double-digit organic growth (2025)
- Use cases: surgical workflows, sterile reprocessing
- Path: Star → SaaS Cash Cow with recurring revenues
Getinge 2025: Growth engines-ventilators, ECMO, Paragonix, life‑science ports, digital health
Getinge's 2025 Stars: Ventilators (11.5% share; SEK 9.2bn sales; 26k units/yr; SEK 420m R&D), Life Science sterile ports (25-30% share), ECMO consumables (recurring sales → 66% group recurring; Rotaflow EU MDR 2025), Paragonix/KidneyVault (>20% sales growth; 18% EBITA), Digital Health (SEK 1,452m R&D; double-digit organic growth).
| Product | Key 2025 metrics |
|---|---|
| Ventilators | 11.5% share; SEK 9.2bn; 26k units; SEK 420m R&D |
| Life Science ports | 25-30% market share |
| ECMO consumables | 66% recurring sales; Rotaflow MDR 2025 |
| Paragonix | >20% sales growth; 18% EBITA |
| Digital Health | SEK 1,452m R&D; double-digit growth |
What is included in the product
Detailed Word Document
BCG Matrix review of Getinge's units: strategic moves for Stars, Cash Cows, Question Marks, and Dogs amid sector trends and risks
Customizable Excel Spreadsheet
One-page Getinge BCG Matrix placing each business unit in a quadrant for quick strategic clarity.
Cash Cows
Operating Tables and Surgical Furniture
Getinge's operating tables and surgical furniture, led by Maquet Corin, held a market-leading share in 2025 and provided Surgical Workflows with stable cash generation-the segment reported roughly SEK 4.2 billion in revenue and ~18% operating margin in FY2025.
As a mature, low-growth market, it produced free cash flow of about SEK 1.1 billion in 2025, funding R&D in high-growth areas.
2025 headwinds from currency swings and tariffs trimmed near-term margins by ~150 basis points, but order backlog entering 2026 rose ~12% year-over-year, confirming its milkable status.
Sterile Reprocessing and Infection Control Hardware
The Infection Control sterile reprocessing business is a cash cow for Getinge, funding corporate debt service and the 2025 dividend of SEK 4.75 per share; the segment delivered roughly SEK 18.2 billion in revenue in FY2025 and ~28% operating margin. Getinge and Steris control ~42% of the global sterilization equipment market, which grows at a 5.1% CAGR. High-volume steam sterilizers and washers drive steady margins and low promo spend, generating predictable free cash flow of about SEK 3.4 billion in 2025. The 2025 Automatiq robotics launch targets efficiency gains in this mature market, not high-growth share capture.
Endovascular Vessel Harvesting (EVH) Systems
The Vasoview Hemopro system is a Cash Cow for Getinge, holding an estimated >50% share of the mature US EVH market and generating high margins; FY2025 revenue from the EVH line is approx. SEK 1.1 billion, supporting operating margin near 28%.
Vasoview Hemopro 3 launched in the US in 2025 focused on incremental improvements-device durability and workflow-preserving share without heavy placement spend, keeping annual maintenance and consumable attach rates ~35%.
Strong recurring consumable sales and a stable installed base require low new-capex, freeing cash to offset Life Science and Bio-Processing volatility, smoothing Getinge group free cash flow by roughly SEK 600-800 million in 2025.
Intra-Aortic Balloon Pumps (IABP) and Cardiosave
Getinge's Intra-Aortic Balloon Pumps (IABP), led by Cardiosave, deliver ~60% US market share and were a steady cash cow for Acute Care Therapies in FY2025, driving high-margin disposable revenue.
In late 2025 Getinge regained CE Mark for Cardiosave, resumed EU deliveries, and reinforced its mature life‑support niche with a large installed base.
CEO Mattias Perjos reported disposables stayed resilient at 7% of Getinge's total revenue in FY2025 despite FDA transition advisories, underpinning recurring margin streams.
- 60% US market share in IABP (Cardiosave)
- CE Mark regained late 2025 - EU deliveries resumed
- Disposables = 7% of total revenue in FY2025
- High installed base → steady high‑margin consumable sales
Technical Service and Spare Parts Contracts
Technical Service and Spare Parts Contracts are Getinge's prime Cash Cow, driving a record 66% recurring revenue share by end-2025 and delivering high gross margins from long-term hospital contracts.
These services need minimal capex versus hardware, grew steadily in 2025, and cushioned SEK 1.0 billion of tariff and FX headwinds.
They exploit Getinge's massive global installed base, yielding predictable, high-margin cash flow and repeatable upsell paths.
- 66% recurring revenue share (2025)
- Low capex vs hardware; high gross margins
- Buffered SEK 1.0bn tariff/FX impact in 2025
- Scales from global installed base; strong upsell
Getinge's SEK 6.3-6.6bn 2025 cash engine: Infection Control + Services power FCF
Getinge cash cows-Surgical Workflows (SEK 4.2bn rev, 18% op margin), Infection Control (SEK 18.2bn, 28% op margin, SEK 3.4bn FCF), EVH Vasoview (SEK 1.1bn, ~28% margin), IABP Cardiosave (60% US share), Services/spares (66% recurring rev, buffered SEK 1.0bn FX/tariff)-total FCF contribution ~SEK 6.3-6.6bn in 2025.
| Segment | 2025 Rev (SEK) | Op Margin | FCF 2025 (SEK) |
|---|---|---|---|
| Surgical | 4.2bn | 18% | 1.1bn |
| Infection Control | 18.2bn | 28% | 3.4bn |
| EVH Vasoview | 1.1bn | 28% | - |
| Services/Spare Parts | - | - | 600-800m |
What You're Viewing Is Included
Getinge BCG Matrix
The file you're previewing is the exact Getinge BCG Matrix you'll receive after purchase-no watermarks, no demo placeholders, just the fully formatted, analysis-ready report tailored for strategic clarity and immediate use.
GETINGE BCG MATRIX TEMPLATE RESEARCH
Unlock Strategic Clarity
Getinge's BCG Matrix preview highlights how its core product lines map to market growth and relative share-hinting at Stars in advanced OR solutions, Cash Cows in sterilization, and Question Marks in emerging digital therapies; this snapshot helps prioritize where management should invest or divest. Purchase the full BCG Matrix for quadrant-by-quadrant data, actionable recommendations, and downloadable Word and Excel files to guide capital allocation and product strategy with confidence.
Stars
Advanced Mechanical Ventilators and ICU Solutions
Getinge holds an 11.5% global ventilator market share at end-2025, benefiting from industry consolidation and an 8.6% sector CAGR; ventilators remain a top revenue driver after generating SEK 9.2bn in 2025 sales for advanced respiratory care.
Production capacity increased to 26,000 units/year to meet aging populations and rising chronic respiratory disease; ongoing R&D spend of SEK 420m in 2025 targets AI-enabled monitoring and automated ventilation modes.
The 2025 Servo-c launch in India and other emerging markets boosted unit shipments by 18% year-over-year, reinforcing this high-growth, high-share Star position in Getinge's portfolio.
Sterile Transfer Systems and Life Science Solutions
Getinge's Life Science hit record 2025 sales, led by DPTE® Sterile Transfer with 45,000 units in operation and DPTE-BetaBag® single-use variants growing at a 12.5% CAGR and over 2 million lifetime units.
As biologics and personalized medicine expand, Getinge holds a 25-30% combined market share in sterile ports, marking dominant positioning.
High growth requires heavy capital: 2025 capex rose to support manufacturing automation and global expansion, sustaining the competitive moat.
Extracorporeal Life Support (ECLS) Consumables
Extracorporeal Life Support (ECLS) consumables-oxygenators and tubing sets-are a Star for Getinge, driven by strong organic growth through 2025 and the Cardiohelp ECMO system anchoring critical-care adoption.
Market forecasts peg the ECMO consumables market at $790 million by 2034; Getinge's consumables and disposables contributed to a recurring-revenue share that rose to 66% of Group sales by late 2025.
Getinge maintains a leading ECMO position; Rotaflow consumables secured EU MDR approval in late 2025, but ongoing investment is essential to meet regulatory demands and scale production against rising global demand.
Transplant Care and Paragonix Integration
Getinge's 2024 Paragonix acquisition became a Star, driving >20% sales growth in FY2025 and lifting segment EBITA to 18%-ahead of company forecasts-on strong KidneyVault uptake after FDA 510(k) clearance.
KidneyVault expands Getinge's transplant portfolio into the largest organ-by-volume market; portable perfusion gives a first-to-market edge in a niche projected to grow ~12% CAGR through 2028.
- 2025 sales growth: >20%
- 2025 segment EBITA margin: ~18%
- KidneyVault: FDA 510(k) cleared (2025)
- Target markets: EU, APAC expansion underway
- Market CAGR (portable perfusion niche): ~12% to 2028
Digital Health Solutions and Hospital Efficiency Software
Getinge's Digital Health Solutions became a Star in 2025, delivering double-digit organic growth as hospitals adopt data-driven workflow optimization and surgical/sterile-reprocessing software that cuts human error.
R&D was SEK 1,452 million in 2025, with a large share into digital platforms now embedded in surgical workflows, driving market share gains and SaaS transition.
These solutions are set to become high-margin Cash Cows as recurring SaaS revenue scales; digital services now represent an increasing portion of aftermarket revenue.
- 2025 R&D: SEK 1,452 million
- Segment: double-digit organic growth (2025)
- Use cases: surgical workflows, sterile reprocessing
- Path: Star → SaaS Cash Cow with recurring revenues
Getinge 2025: Growth engines-ventilators, ECMO, Paragonix, life‑science ports, digital health
Getinge's 2025 Stars: Ventilators (11.5% share; SEK 9.2bn sales; 26k units/yr; SEK 420m R&D), Life Science sterile ports (25-30% share), ECMO consumables (recurring sales → 66% group recurring; Rotaflow EU MDR 2025), Paragonix/KidneyVault (>20% sales growth; 18% EBITA), Digital Health (SEK 1,452m R&D; double-digit organic growth).
| Product | Key 2025 metrics |
|---|---|
| Ventilators | 11.5% share; SEK 9.2bn; 26k units; SEK 420m R&D |
| Life Science ports | 25-30% market share |
| ECMO consumables | 66% recurring sales; Rotaflow MDR 2025 |
| Paragonix | >20% sales growth; 18% EBITA |
| Digital Health | SEK 1,452m R&D; double-digit growth |
What is included in the product
Detailed Word Document
BCG Matrix review of Getinge's units: strategic moves for Stars, Cash Cows, Question Marks, and Dogs amid sector trends and risks
Customizable Excel Spreadsheet
One-page Getinge BCG Matrix placing each business unit in a quadrant for quick strategic clarity.
Cash Cows
Operating Tables and Surgical Furniture
Getinge's operating tables and surgical furniture, led by Maquet Corin, held a market-leading share in 2025 and provided Surgical Workflows with stable cash generation-the segment reported roughly SEK 4.2 billion in revenue and ~18% operating margin in FY2025.
As a mature, low-growth market, it produced free cash flow of about SEK 1.1 billion in 2025, funding R&D in high-growth areas.
2025 headwinds from currency swings and tariffs trimmed near-term margins by ~150 basis points, but order backlog entering 2026 rose ~12% year-over-year, confirming its milkable status.
Sterile Reprocessing and Infection Control Hardware
The Infection Control sterile reprocessing business is a cash cow for Getinge, funding corporate debt service and the 2025 dividend of SEK 4.75 per share; the segment delivered roughly SEK 18.2 billion in revenue in FY2025 and ~28% operating margin. Getinge and Steris control ~42% of the global sterilization equipment market, which grows at a 5.1% CAGR. High-volume steam sterilizers and washers drive steady margins and low promo spend, generating predictable free cash flow of about SEK 3.4 billion in 2025. The 2025 Automatiq robotics launch targets efficiency gains in this mature market, not high-growth share capture.
Endovascular Vessel Harvesting (EVH) Systems
The Vasoview Hemopro system is a Cash Cow for Getinge, holding an estimated >50% share of the mature US EVH market and generating high margins; FY2025 revenue from the EVH line is approx. SEK 1.1 billion, supporting operating margin near 28%.
Vasoview Hemopro 3 launched in the US in 2025 focused on incremental improvements-device durability and workflow-preserving share without heavy placement spend, keeping annual maintenance and consumable attach rates ~35%.
Strong recurring consumable sales and a stable installed base require low new-capex, freeing cash to offset Life Science and Bio-Processing volatility, smoothing Getinge group free cash flow by roughly SEK 600-800 million in 2025.
Intra-Aortic Balloon Pumps (IABP) and Cardiosave
Getinge's Intra-Aortic Balloon Pumps (IABP), led by Cardiosave, deliver ~60% US market share and were a steady cash cow for Acute Care Therapies in FY2025, driving high-margin disposable revenue.
In late 2025 Getinge regained CE Mark for Cardiosave, resumed EU deliveries, and reinforced its mature life‑support niche with a large installed base.
CEO Mattias Perjos reported disposables stayed resilient at 7% of Getinge's total revenue in FY2025 despite FDA transition advisories, underpinning recurring margin streams.
- 60% US market share in IABP (Cardiosave)
- CE Mark regained late 2025 - EU deliveries resumed
- Disposables = 7% of total revenue in FY2025
- High installed base → steady high‑margin consumable sales
Technical Service and Spare Parts Contracts
Technical Service and Spare Parts Contracts are Getinge's prime Cash Cow, driving a record 66% recurring revenue share by end-2025 and delivering high gross margins from long-term hospital contracts.
These services need minimal capex versus hardware, grew steadily in 2025, and cushioned SEK 1.0 billion of tariff and FX headwinds.
They exploit Getinge's massive global installed base, yielding predictable, high-margin cash flow and repeatable upsell paths.
- 66% recurring revenue share (2025)
- Low capex vs hardware; high gross margins
- Buffered SEK 1.0bn tariff/FX impact in 2025
- Scales from global installed base; strong upsell
Getinge's SEK 6.3-6.6bn 2025 cash engine: Infection Control + Services power FCF
Getinge cash cows-Surgical Workflows (SEK 4.2bn rev, 18% op margin), Infection Control (SEK 18.2bn, 28% op margin, SEK 3.4bn FCF), EVH Vasoview (SEK 1.1bn, ~28% margin), IABP Cardiosave (60% US share), Services/spares (66% recurring rev, buffered SEK 1.0bn FX/tariff)-total FCF contribution ~SEK 6.3-6.6bn in 2025.
| Segment | 2025 Rev (SEK) | Op Margin | FCF 2025 (SEK) |
|---|---|---|---|
| Surgical | 4.2bn | 18% | 1.1bn |
| Infection Control | 18.2bn | 28% | 3.4bn |
| EVH Vasoview | 1.1bn | 28% | - |
| Services/Spare Parts | - | - | 600-800m |
What You're Viewing Is Included
Getinge BCG Matrix
The file you're previewing is the exact Getinge BCG Matrix you'll receive after purchase-no watermarks, no demo placeholders, just the fully formatted, analysis-ready report tailored for strategic clarity and immediate use.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Unlock Strategic Clarity
Getinge's BCG Matrix preview highlights how its core product lines map to market growth and relative share-hinting at Stars in advanced OR solutions, Cash Cows in sterilization, and Question Marks in emerging digital therapies; this snapshot helps prioritize where management should invest or divest. Purchase the full BCG Matrix for quadrant-by-quadrant data, actionable recommendations, and downloadable Word and Excel files to guide capital allocation and product strategy with confidence.
Stars
Advanced Mechanical Ventilators and ICU Solutions
Getinge holds an 11.5% global ventilator market share at end-2025, benefiting from industry consolidation and an 8.6% sector CAGR; ventilators remain a top revenue driver after generating SEK 9.2bn in 2025 sales for advanced respiratory care.
Production capacity increased to 26,000 units/year to meet aging populations and rising chronic respiratory disease; ongoing R&D spend of SEK 420m in 2025 targets AI-enabled monitoring and automated ventilation modes.
The 2025 Servo-c launch in India and other emerging markets boosted unit shipments by 18% year-over-year, reinforcing this high-growth, high-share Star position in Getinge's portfolio.
Sterile Transfer Systems and Life Science Solutions
Getinge's Life Science hit record 2025 sales, led by DPTE® Sterile Transfer with 45,000 units in operation and DPTE-BetaBag® single-use variants growing at a 12.5% CAGR and over 2 million lifetime units.
As biologics and personalized medicine expand, Getinge holds a 25-30% combined market share in sterile ports, marking dominant positioning.
High growth requires heavy capital: 2025 capex rose to support manufacturing automation and global expansion, sustaining the competitive moat.
Extracorporeal Life Support (ECLS) Consumables
Extracorporeal Life Support (ECLS) consumables-oxygenators and tubing sets-are a Star for Getinge, driven by strong organic growth through 2025 and the Cardiohelp ECMO system anchoring critical-care adoption.
Market forecasts peg the ECMO consumables market at $790 million by 2034; Getinge's consumables and disposables contributed to a recurring-revenue share that rose to 66% of Group sales by late 2025.
Getinge maintains a leading ECMO position; Rotaflow consumables secured EU MDR approval in late 2025, but ongoing investment is essential to meet regulatory demands and scale production against rising global demand.
Transplant Care and Paragonix Integration
Getinge's 2024 Paragonix acquisition became a Star, driving >20% sales growth in FY2025 and lifting segment EBITA to 18%-ahead of company forecasts-on strong KidneyVault uptake after FDA 510(k) clearance.
KidneyVault expands Getinge's transplant portfolio into the largest organ-by-volume market; portable perfusion gives a first-to-market edge in a niche projected to grow ~12% CAGR through 2028.
- 2025 sales growth: >20%
- 2025 segment EBITA margin: ~18%
- KidneyVault: FDA 510(k) cleared (2025)
- Target markets: EU, APAC expansion underway
- Market CAGR (portable perfusion niche): ~12% to 2028
Digital Health Solutions and Hospital Efficiency Software
Getinge's Digital Health Solutions became a Star in 2025, delivering double-digit organic growth as hospitals adopt data-driven workflow optimization and surgical/sterile-reprocessing software that cuts human error.
R&D was SEK 1,452 million in 2025, with a large share into digital platforms now embedded in surgical workflows, driving market share gains and SaaS transition.
These solutions are set to become high-margin Cash Cows as recurring SaaS revenue scales; digital services now represent an increasing portion of aftermarket revenue.
- 2025 R&D: SEK 1,452 million
- Segment: double-digit organic growth (2025)
- Use cases: surgical workflows, sterile reprocessing
- Path: Star → SaaS Cash Cow with recurring revenues
Getinge 2025: Growth engines-ventilators, ECMO, Paragonix, life‑science ports, digital health
Getinge's 2025 Stars: Ventilators (11.5% share; SEK 9.2bn sales; 26k units/yr; SEK 420m R&D), Life Science sterile ports (25-30% share), ECMO consumables (recurring sales → 66% group recurring; Rotaflow EU MDR 2025), Paragonix/KidneyVault (>20% sales growth; 18% EBITA), Digital Health (SEK 1,452m R&D; double-digit organic growth).
| Product | Key 2025 metrics |
|---|---|
| Ventilators | 11.5% share; SEK 9.2bn; 26k units; SEK 420m R&D |
| Life Science ports | 25-30% market share |
| ECMO consumables | 66% recurring sales; Rotaflow MDR 2025 |
| Paragonix | >20% sales growth; 18% EBITA |
| Digital Health | SEK 1,452m R&D; double-digit growth |
What is included in the product
Detailed Word Document
BCG Matrix review of Getinge's units: strategic moves for Stars, Cash Cows, Question Marks, and Dogs amid sector trends and risks
Customizable Excel Spreadsheet
One-page Getinge BCG Matrix placing each business unit in a quadrant for quick strategic clarity.
Cash Cows
Operating Tables and Surgical Furniture
Getinge's operating tables and surgical furniture, led by Maquet Corin, held a market-leading share in 2025 and provided Surgical Workflows with stable cash generation-the segment reported roughly SEK 4.2 billion in revenue and ~18% operating margin in FY2025.
As a mature, low-growth market, it produced free cash flow of about SEK 1.1 billion in 2025, funding R&D in high-growth areas.
2025 headwinds from currency swings and tariffs trimmed near-term margins by ~150 basis points, but order backlog entering 2026 rose ~12% year-over-year, confirming its milkable status.
Sterile Reprocessing and Infection Control Hardware
The Infection Control sterile reprocessing business is a cash cow for Getinge, funding corporate debt service and the 2025 dividend of SEK 4.75 per share; the segment delivered roughly SEK 18.2 billion in revenue in FY2025 and ~28% operating margin. Getinge and Steris control ~42% of the global sterilization equipment market, which grows at a 5.1% CAGR. High-volume steam sterilizers and washers drive steady margins and low promo spend, generating predictable free cash flow of about SEK 3.4 billion in 2025. The 2025 Automatiq robotics launch targets efficiency gains in this mature market, not high-growth share capture.
Endovascular Vessel Harvesting (EVH) Systems
The Vasoview Hemopro system is a Cash Cow for Getinge, holding an estimated >50% share of the mature US EVH market and generating high margins; FY2025 revenue from the EVH line is approx. SEK 1.1 billion, supporting operating margin near 28%.
Vasoview Hemopro 3 launched in the US in 2025 focused on incremental improvements-device durability and workflow-preserving share without heavy placement spend, keeping annual maintenance and consumable attach rates ~35%.
Strong recurring consumable sales and a stable installed base require low new-capex, freeing cash to offset Life Science and Bio-Processing volatility, smoothing Getinge group free cash flow by roughly SEK 600-800 million in 2025.
Intra-Aortic Balloon Pumps (IABP) and Cardiosave
Getinge's Intra-Aortic Balloon Pumps (IABP), led by Cardiosave, deliver ~60% US market share and were a steady cash cow for Acute Care Therapies in FY2025, driving high-margin disposable revenue.
In late 2025 Getinge regained CE Mark for Cardiosave, resumed EU deliveries, and reinforced its mature life‑support niche with a large installed base.
CEO Mattias Perjos reported disposables stayed resilient at 7% of Getinge's total revenue in FY2025 despite FDA transition advisories, underpinning recurring margin streams.
- 60% US market share in IABP (Cardiosave)
- CE Mark regained late 2025 - EU deliveries resumed
- Disposables = 7% of total revenue in FY2025
- High installed base → steady high‑margin consumable sales
Technical Service and Spare Parts Contracts
Technical Service and Spare Parts Contracts are Getinge's prime Cash Cow, driving a record 66% recurring revenue share by end-2025 and delivering high gross margins from long-term hospital contracts.
These services need minimal capex versus hardware, grew steadily in 2025, and cushioned SEK 1.0 billion of tariff and FX headwinds.
They exploit Getinge's massive global installed base, yielding predictable, high-margin cash flow and repeatable upsell paths.
- 66% recurring revenue share (2025)
- Low capex vs hardware; high gross margins
- Buffered SEK 1.0bn tariff/FX impact in 2025
- Scales from global installed base; strong upsell
Getinge's SEK 6.3-6.6bn 2025 cash engine: Infection Control + Services power FCF
Getinge cash cows-Surgical Workflows (SEK 4.2bn rev, 18% op margin), Infection Control (SEK 18.2bn, 28% op margin, SEK 3.4bn FCF), EVH Vasoview (SEK 1.1bn, ~28% margin), IABP Cardiosave (60% US share), Services/spares (66% recurring rev, buffered SEK 1.0bn FX/tariff)-total FCF contribution ~SEK 6.3-6.6bn in 2025.
| Segment | 2025 Rev (SEK) | Op Margin | FCF 2025 (SEK) |
|---|---|---|---|
| Surgical | 4.2bn | 18% | 1.1bn |
| Infection Control | 18.2bn | 28% | 3.4bn |
| EVH Vasoview | 1.1bn | 28% | - |
| Services/Spare Parts | - | - | 600-800m |
What You're Viewing Is Included
Getinge BCG Matrix
The file you're previewing is the exact Getinge BCG Matrix you'll receive after purchase-no watermarks, no demo placeholders, just the fully formatted, analysis-ready report tailored for strategic clarity and immediate use.
